Otsuka and ReCor Announce Merger Agreement

 

July 10, 2018—Otsuka Holdings Co., Ltd., Otsuka Medical Devices Co., Ltd., and ReCor Medical, Inc. announced the signing of a merger agreement pursuant to which Otsuka Holdings will acquire the remaining shares in ReCor from its current holders. The transaction is subject to approval by ReCor’s shareholders.

The acquisition comes after the announcement by ReCor that the US Food and Drug Administration has granted approval to initiate a pivotal clinical study, RADIANCE II, for the evaluation of the company's Paradise renal denervation system for safe and effective reduction of blood pressure in patients with hypertension.

Results of the RADIANCE-HTN SOLO study of the Paradise system, which met its primary efficacy endpoint and demonstrated a statistically significant reduction in blood pressure in hypertensive patients, were presented at the EuroPCR 2018 meeting held May 21–25 in Paris, France, and simultaneously published by Professor Michel Azizi, MD, et al in The Lancet (2018;391:2335–2345).

Following the acquisition, ReCor plans to continue to develop and evaluate the Paradise system in patients with hypertension in preparation for worldwide commercialization, as well as explore its use in additional clinical applications such as heart failure, kidney disease, and metabolic disorders, while also building the Otsuka Medical Devices’ incubation and clinical development hub in the United States and Europe.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.